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The synthesis of new modified indolo[3,2-c]quinoline ligands L
1-L
8 with metal-binding sites
is reported. By coordination to ruthenium- and osmium-arene moieties 16 complexes of the type
[(η
6-p-cymene)M(L)Cl]Cl (1a,b-8a,b), where M is Ru
II or Os
II and L is L
1-L
8, have been prepared.
All compounds were comprehensively characterized by elemental analysis, electrospray ionization
mass spectrometry, IR, UV-vis, and NMR spectroscopy, thermogravimetric analysis, and single-
crystal X-ray diffraction (2a, 4a, 4b, 5a, 7a, and 7b). The complexes were tested for antiproliferative
activity in vitro in three human cancer cell lines, namely, CH1 (ovarian carcinoma), SW480 (colon
adenocarcinoma), and A549 (non-small-cell lung cancer), yielding IC50 values in the submicromolar
or low micromolar range.
Introduction
Triggered by the success of flavopiridol, the first cyclin-
dependent kinase (cdk) inhibitor under clinical investiga-
tion,
1 efforts have been focused on the development of
targeted ruthenium complexes,
2-9 among them some with
kinase-inhibitory properties.
10,11 Indolo[3,2-d]benzaze-
pines, also referred to as paullones, were identified as puta-
tive cdk inhibitors by analysis of the National Cancer
Institute (NCI) Human Tumor Cell Line Anti-Cancer Drug
Screen Database.
12 Experiments with enzyme assays con-
firmed the assumption, and a larger series of paullones was
evaluated for their biological activity.
13-15
In order to overcome limitations of confined water solu-
bility and bioavailability of these organic compounds, they
were complexed with metal ions. As the paullone backbone
itself is not suitable for coordination to metals, except for
binding via lactam (or thiolactam) groups yielding thermo-
dynamically nonstable four-membered metallocycles, metal-
binding sites had to be created at the periphery of the molecule






physicochemical and biological properties could be altered
markedly. Structure-activity relationship studies have shown
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that an intact lactam unit is favorable for cdk inhibition.
13,22,23
In vitro cytotoxicity of ruthenium and osmium complexes was,
however, found to be higher if complexation occurred via the
modified lactam group and not through a chelator group at
position 9 of the paullone backbone.
20
Paullones contain a seven-membered folded azepine ring,
which makes the whole molecule nonplanar (Chart 1). Re-
cently, efforts by us were extended to indolo[3,2-c]quinolines
(Chart 1) that have a framework similar to that of paullones
but comprise a flat six-membered ring instead of the folded
seven-membered azepine ring, making the whole heteroaro-
matic system planar. The antiproliferative properties of this




osmium complexes showed a significantly higher in vitro
cytotoxicity compared to that of the related paullone com-
plexes.Inaddition,theindoloquinolinesrevealedahighpoten-
tial for intercalation into DNA and caused concentration-
dependent cell cycle perturbations. However, the reported
metal complexes of indolo[3,2-c]quinolines showed a much
lower stability in both organic and aqueous media, in some
cases leading to rapid dissociation of the ligands from the
metal-arene scaffold.
11
With the intention to increase the hydrolytic stability of
metal complexes by involvement of sp
2-hybridized nitrogen
donors, we suggested performing condensation reactions of
the indoloquinoline hydrazine with 2-formyl- and/or 2-acet-
ylpyridine and to bind the resulting Schiff base ligands to
ruthenium(II)-arene and osmium(II)-arene moieties, tak-
ing into account the different kinetics of ligand exchange
reactions at ruthenium(II) and osmium(II).
30 Looking for
structure-activity relationships to be elucidated in this class
of complexes, we intended to study the effect of substitution
in position 2 of the parent indoloquinoline on the antipro-
liferative activity.
Herein we report on the synthesis of 16 novel ruthe-
nium(II)-areneandosmium(II)-arenecomplexeswithmodified
indolo[3,2-c]quinolines 1a,b-8a,b (Scheme 1, Chart 2), of
which six were characterized by X-ray diffraction, their spec-
troscopic properties (NMR, UV-vis, FT-IR), thermal beha-
vior, and ESI mass spectra. The cytotoxic activity of these
metal complexes assayed in vitro in three human cancer cell
lines, CH1 (ovarian carcinoma), SW480 (colon adeno-
carcinoma), and A549 (non-small-cell lung carcinoma), is also
reported.
Experimental Section
Characterization of the Compounds. One-dimensional
1H and
13CN M Ra n dt w o - d i m e n s i o n a l
1H-












13C HMBC NMR spectra were recorded on two
Bruker Avance III spectrometers at 500.32 or 500.10 (
1H), and
125.82 or 125.76 (
13C) MHz, respectively, by using as a solvent
DMSO-d6 or MeOD-d4 at room temperature and standard
pulse programs.
1H and
13C shifts are quoted relative to the
solvent residual signals. The atom numbering used for assign-
ments is depicted in Chart S1. IR spectra were measured on a
Bruker Vertex 70 FT-IR spectrometer by means of attenuated
total reflection (ATR) technique, and UV-vis spectra were
recorded with a Perkin-Elmer Lambda 650 spectrophotometer
equipped with a six-cell changer and a Peltier element for
temperature control. Electrospray ionization mass spectrome-
try (ESI-MS) was carried out with a Bruker Esquire 3000
instrument; the samples were dissolved in methanol. Thermo-
gravimetric analysis (TGA) and differential thermal analysis
(DTA) were carried out on a Mettler Toledo TGA/SDTA 851
e
instrument. All elemental analyses were performed at the
Microanalytical Laboratory of the University of Vienna with a
Perkin-Elmer 2400 CHN elemental analyzer.
Synthesis of the Ligands. Ethanol was dried using standard
procedures. 2-Aminobenzylamine and substituted indole-2,3-
diones were purchased from Aldrich and used as received.
Indoloquinolines A were synthesized by reaction of 2-amino-
benzylamine with indole-2,3-diones in acetic acid and further
chlorinated with phosphorus oxychloride to derivatives B by
following the procedures reported previously (Scheme 1).
24,25,29
Compounds B were heated in neat hydrazine hydrate under an
Ar atmosphere for 24-29 h, and after cooling, compounds C
were filtered off, washed with water and diethyl ether, dried
in vacuo, and used without further purification. Acetylpyridine
hydrazone was prepared as described elsewhere.
31
General Procedure A. To the corresponding 11H-indolo[3,2-c]-
quinolin-6-yl)hydrazine (1 equiv) in a 25 mL Schlenk tube was
addedasolutionof2-formylpyridine(1.1equiv)or2-acetylpyri-
dine (1.1 equiv) in ethanol, and the resulting mixture was stirred
underanargonatmospherefor24h.Themixturewasallowedto
cool to room temperature; the precipitate formed was filtered
off, washed with small amounts of ethanol (2   1 mL) and
diethyl ether (2   2 mL), and dried in vacuo at 50 C.
N-(5,11-Dihydroindolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-
2-yl-methylidene)azine (L
1). General procedure A: (11H-Indolo-
[3,2-c]quinolin-6-yl)hydrazine (500 mg, 2.01 mmol), ethanol
(10 mL), 2-formylpyridine (212 μL, 2.22 mmol). Yield: 607 mg,
89%.Anal.Calcd forC21H15N530.15H2O(Mr340.08):C,74.17;
H, 4.53; N, 20.59. Found: C, 74.09; H, 4.46; N, 20.72. ESI-MS
(methanol), positive: m/z 338 [M þ H]
þ,3 6 0[ M þ Na]
þ.I R
(ATR, selected bands, νmax): 3337, 2935, 2830, 1631, 1569,




2). General procedure A: (11H-Indolo-
[3,2-c]quinolin-6-yl)hydrazine (500 mg, 2.01 mmol), ethanol
(10 mL), 2-acetylpyridine (248 μL, 2.22 mmol). Yield: 561 mg, 76%.
Chart 1. Indolo[3,2-d]benzazepine (left) and Indolo[3,2-
c]quinoline (right) Backbones with Atom-Numbering Schemes
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Anal. Calcd for C22H17N530.15H2O( Mr 354.11): C, 74.62;
H, 4.92; N, 19.78. Found: C, 74.44; H, 4.58; N, 19.89. ESI-MS
(methanol), positive: m/z 352 [M þ H]
þ,3 7 4[ Mþ Na]
þ.I R
(ATR, selected bands, νmax): 3353, 3085, 2955, 1627, 1534, 1456,




3). General procedure A: (2-Fluoro-
11H-indolo[3,2-c]quinolin-6-yl)hydrazine (800 mg, 3.01 mmol),
ethanol (10 mL), 2-acetylpyridine (371 μL, 3.31 mmol). Yield:
1040mg,94%.Anal.CalcdforC22H16N5F(Mr369.39):C,71.53;
H, 4.37; N, 18.96. Found: C, 71.37; H, 4.13; N, 18.72. ESI-MS
(methanol), positive: m/z 370 [M þ H]
þ,3 9 2[ Mþ Na]
þ.I R
(ATR, selected bands, νmax): 3349, 3083, 2956, 2919, 2876, 1162,





4). General procedure A:
(2-Chloro-11H-indolo[3,2-c]quinolin-6-yl)hydrazine (700 mg, 2.48
mmol), ethanol (10 mL), 2-formylpyridine (260 μL, 2.72 mmol).
Yield: 599 mg, 65%. Anal. Calcd for C21H14N5Cl30.25H2O( Mr
376.33): C, 67.12; H, 3.88; N, 18.61. Found: C, 67.16; H, 3.81; N,
18.44.ESI-MS(methanol),positive:m/z372[MþH]
þ.IR(ATR,
selected bands, νmax): 3339, 3060, 2752, 1631, 1567, 1529, 1217,





11H-indolo[3,2-c]quinolin-6-yl)hydrazine (700 mg, 2.48 mmol),
ethanol (10 mL), 2-acetylpyridine (303 μL, 2.72 mmol). Yield:
640 mg, 67%. Anal. Calcd for C22H16N5Cl (Mr 385.85): C, 68.48;




selected bands, νmax): 3335, 3104, 2955, 1629, 1542, 1453, 1429,





11H-indolo[3,2-c]quinolin-6-yl)hydrazine (800 mg, 2.45 mmol),
ethanol (10 mL), 2-acetylpyridine (300 μL, 2.72 mmol). Yield:
890 mg, 84%. Anal. Calcd for C22H16N5Br30.1H2O( Mr 432.10):
C,61.15;H,3.78;N,16.21.Found:C,61.01;H,3.59;N,16.29.ESI-
MS (methanol), positive: m/z 432 [M þ H]
þ. IR (ATR, selected
bands, νmax): 3331, 3076, 2954, 1628, 1538, 1452, 1428, 1405, 1275,




7). General procedure A: (2-Meth-
yl-11H-indolo[3,2-c]quinolin-6-yl)hydrazine(800mg,3.05mmol),
ethanol(8mL),2-acetylpyridine(376μL,3.36mmol).Anal.Calcd
for C23H19N530.2H2O( Mr 369.03): C, 74.86; H, 5.30; N, 18.98.




selected bands, νmax): 3352, 3037, 2964, 2870, 1630, 1598, 1530,




8). A mixture of 6-chloro-2-nitro-
11H-indolo[3,2-c]quinoline (1000 mg, 3.36 mmol), 2-acetylpyri-
dine hydrazone (730 mg, 5.40 mmol), and 1-butanol (10 mL) in a
Schlenk tube under argon atmosphere was heated at 130 Cf o r
27 h. After cooling to room temperature, the solid formed was
filteredoff,washedwithwater(4 5mL)a ndethanol(2 2mL),
and dried in vacuo. Further purification was performed by dissolu-
tion of the product in ethyl acetate (1.5 L/g) and washing the
organic phase with half saturated aqueous NaHCO3 solution
(5   300 mL) and brine (2   300 mL). The solvent was removed
underreduced pressure, and the product was dried in vacuo.
Scheme 1. Synthesis of the Modified Indoloquinoline Ligands
a
aReagentsandconditions:(i)HOAc,Ar,140C,4h;(ii)POCl3,Ar,140C,24-27h;(iii)N2H43H2O,Ar,120C,24-29h;(iv)EtOH,Ar,65C,24h;
(v) 1-butanol, Ar, 130 C, 27 h.
Chart 2. Ruthenium(II)- and Osmium(II)-Arene Complexes
with Modified Indoloquinoline Ligands
a
aUnderlined compounds have been characterized by X-ray crystal-
lography.276 Organometallics, Vol. 30, No. 2, 2011 Filak et al.
Yield: 1194 mg, 90%. Anal. Calcd for C22H16N6O230.25H2O( Mr
400.91):C,65.91;H,4.15;N,20.96.Found:C,65.95;H,4.43;N,20.88.




1319, 1270, 1146, 1095, 1014, 791, 734, 676, 609, 589 cm
-1.








prepared according to the literature.
General Procedure B. To a mixture of the corresponding
ligand (1 equiv) and [MCl2(p-cymene)2]2 (0.5 equiv), where M
is Ru or Os, in a 25 mL Schlenk tube was added dry ethanol
under Ar at room temperature. The resulting solution was
protectedfromlightandstirredfor24h.Theprecipitateformed
was collected under suction, washed with a small amount of
ethanol (1-2 mL) and diethyl ether (2   5-10 mL), and dried
in vacuo at 47-50 C under light protection.
General Procedure C. To a mixture of the corresponding
ligand (1 equiv) [MCl2(p-cymene)2]2 (0.5 equiv), where M is
Ru or Os, in a 25 mL Schlenk tube was added dry ethanol under
Ar. The resulting solution was protected from light and stirred
at room temperature for 24 h. The precipitate formed was
collected under suction, washed with a small amount of ethanol
(1-2mL)anddiethylether(2 5-10mL),anddriedinvacuoat
47 C under light protection. To the mother liquor was added
diethyl ether (15-20 mL), whereupon a second crop of product
wasprecipitated.Thissolidwasalsocollectedundersuctionand
driedinvacuoat47-50Cunderlightprotection.Inallcasesthe




Chloride (1a). General procedure B: N-(5,11-Dihydroindolo-
[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-2-yl-methylidene)azine
(200mg,0.59mmol),[RuCl2(p-cymene)2]2(182mg,0.30mmol),
ethanol (5 mL). Yield: 337 mg, 88% (yellow solid). Anal. Calcd
for C31H29N5Cl2Ru31.5H2O( Mr 670.59): C, 55.52; H, 4.81; N,
10.44. Found: C, 55.54; H, 4.69; N, 10.37. ESI-MS (methanol),
positive: m/z 608 [M - Cl]
þ. IR (ATR, selected bands, νmax):
3655,3412,2967,2868,1628,1590,1527,1466,1400,1228,1008,
777, 751, 718, 704 cm
-1.
1H NMR (500 MHz, CD3OD):
δ 9.44 (d, 1H,
3J = 5.6 Hz, H
18), 8.72 (s, 1H, H







21), 7.81 (d, 1H,
3J = 8.4 Hz, H
4), 7.73-7.67 (m, 2H,
H
10þH
19), 7.63-7.58 (m, 1H, H
3), 7.51-7.47 (m, 1H, H
9),
7.45-7.41 (m, 1H, H
2), 7.39-7.35 (m, 1H, H
8), 5.87 (d, 1H,
3J = 6.1 Hz, H
cy2), 5.65 (d, 1H,
3J = 6.1 Hz, H
cy1), 5.62 (d, 1H,
3J = 6.2 Hz, H
cy20
), 5.21 (d, 1H,















NMR (125 MHz, CD3OD): δ 156.4 (CH, C








4a), 129.6 (CH, C
3), 126.3 (CH, C
19), 126.3 (CH,
C
21), 124.8 (CH, C
9), 123.5 (Cq, C




7), 121.4 (CH, C
8), 117.0 (CH, C
4), 113.3 (Cq, C
11b),
111.5 (CH, C
10), 105.1 (Cq, C
cy2a), 104.1 (Cq, C
6a), 103.7 (Cq,
C
cy1a), 87.0 (CH, C
cy20
), 85.9 (CH, C




), 31.1 (CH, C
cy3), 21.0 (CH3, C









Chloride (1b). General procedure B: N-(5,11-Dihydroindolo-
[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-2-yl-methylidene)azine
(170 mg, 0.50 mmol), [OsCl2(p-cymene)2]2 (199mg, 0.25mmol),
ethanol (4.5 mL). Yield: 298 mg, 81% (yellow solid). Anal.
Calcd for C31H29N5Cl2Os31.5H2O( Mr 759.75): C, 49.01; H,
4.25; N, 9.22. Found: C, 49.05; H, 4.07; N, 9.06. ESI-MS
(methanol), positive: m/z 698 [M - Cl]
þ, 662 [M - Cl - HCl]
þ.
IR (ATR, selected bands, νmax): 3656, 3398, 2963, 2869, 1628,






18), 9.13 (s, 1H, H
14), 8.39 (d, 1H,
3J = 8.0 Hz, H
7),
8.21-8.12 (m, 3H, H
1þH
20þH




19), 7.62-7.57 (m, 1H, H
3), 7.51-7.47 (m, 1H, H
9),
7.46-7.42 (m, 1H, H
2), 7.40-7.35 (m, 1H, H
8), 6.16 (d, 1H,
3J =
5.8 Hz, H
cy2), 5.92-5.88 (m, 2H, H
cy1þH
cy20








3J =6 . 9H z ,H
cy40
), 1.08 (d, 3H,
3J = 6.9 Hz, H




13C NMR (125 MHz, CD3OD): δ 157.6 (CH,
C
14), 156.1 (Cq, C
16), 155.1 (CH, C








3), 127.1 (CH, C
19), 126.0 (CH, C
21), 124.8 (CH, C
9), 123.5 (Cq,
C
6b), 123.3 (CH, C
2), 121.9(CH, C
1), 121.9 (CH, C
7), 121.4(CH,
C
8), 116.9 (CH, C
4), 113.2 (Cq, C









cy2), 76.4 (CH, C
cy1), 74.5 (CH, C
cy10
), 31.3 (CH, C
cy3), 21.2
(CH3, C
cy4), 20.9 (CH3, C
cy40
), 17.6 (CH3, C




Chloride (2a). General procedure B: N-(5,11-Dihydroindolo-
[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-2-yl-ethylidene)azine
(200 mg, 0.57 mmol), [RuCl2(p-cymene)2]2 (175 mg, 0.29
mmol), ethanol (5 mL). Yield: 282 mg, 75% (orange solid).
Anal. Calcd for C32H31N5Cl2Ru31.5H2O( Mr 684.62): C,
56.14; H, 5.01; N, 10.23. Found: C, 56.22; H, 4.98; N, 10.22.
ESI-MS (methanol), positive: m/z 622 [M - Cl]





MHz, CD3OD): δ 10.59 (br s, 1H, H
5), 9.50 (d, 1H,
3J =5 . 4
Hz, H
18), 8.50 (d, 1H,
3J =8 . 0H z ,H
7), 8.26-8.22 (m, 1H,
H
20), 8.20 (d, 1H,
3J =7 . 9H z ,H
1), 8.13 (d, 1H,
3J =7 . 9H z ,
H
21), 7.77-7.73 (m, 2H, H
4þH
19), 7.71 (d, 1H,
3J =8 . 2H z ,
H
10), 7.60-7.55 (m, 1H, H
3), 7.52-7.47 (m, 1H, H
9),
7.44-7.38 (m, 2H, H
2þH
8), 5.89 (d, 1H,














cy3), 2.22 (s, 3H, H
cy5), 1.15 (d, 3H,




3J =6 . 9H z ,H
cy4)p p m ,H
11 not obsd.
13CN M R( 1 2 5
MHz, CD3OD): δ 165.5 (Cq, C
14). 155.6 (Cq, C
16), 155.4 (Cq,
C
18), 147.9 (Cq, C
6), 139.5 (CH, C
20), 139.2 (Cq, C
11a), 138.8
(Cq, C
10a), 136.5 (Cq, C
4a), 129.5 (CH, C
3), 126.5 (CH, C
19),
125.7 (CH, C
21), 124.7 (CH, C
9), 123.7 (Cq, C
6b), 123.0 (CH,
C
2), 121.9 (CH, C
1), 121.8 (CH, C
7), 121.4 (CH, C
8), 116.9
(CH, C
4), 113.2 (Cq, C
11b), 111.5 (CH, C
10), 104.5 (Cq, C
cy2a),
104.2 (Cq, C
6a), 103.8 (Cq, C




cy2), 85.6 (CH, C
cy1), 84.0 (CH, C
cy10
), 31.0 (CH, C
cy3), 21.0
(CH3, C
cy4), 20.7 (CH3, C
cy40







ride (2b). General procedure C: N-(5,11-Dihydroindolo[3,2-c]-
quinolin-6-ylidene)-N0-(1-pyridin-2-yl-ethylidene)azine (188 mg,
0.57 mmol), [OsCl2(p-cymene)2]2 (212 mg, 0.27 mmol, ethanol
(4.8mL).Yield:269mgþ66mg,84%(orangesolid).Anal.Calcd
forC32H31N5Cl2Os32H2O(Mr782.79):C,49.10;H,4.51;N,8.95.
Found: C, 49.19; H, 4.44; N, 8.78. ESI-MS (methanol), positive:
m/z 712 [M - Cl]
þ,6 7 6[ M- Cl - HCl]
þ. IR (ATR, selected
bands,νmax):3642,3338,3069,2965,2875,1630,1587,1525,1463,
1400, 1223, 1035, 1011, 745, 698, 637 cm
-1.
1H NMR (500 MHz,
CD3OD): δ 9.43 (d, 1H,
3J =5 . 4H z ,H
18), 8.46 (d, 1H,






4J =0 . 9H z ,H
1), 7.76-7.72 (m, 1H, H
19), 7.71 (d, 1H,
3J =8 . 2
Hz, H
10), 7.62 (d, 1H,
3J =8 . 3H z ,H
4), 7.59-7.54 (m, 1H, H
3),
7.51-7.47 (m, 1H, H
9), 7.44-7.37 (m, 2H, H
2þH
8), 6.17 (d, 1H,
3J = 5.8 Hz, H
cy2), 5.92 (d, 1H,
3J = 5.8 Hz, H
cy20
), 5.87 (d, 1H,
3J =5 . 8H z ,H
cy1), 5.32 (d, 1H,




15)2 . 7 5 -2.66 (m, 1H, H
cy3), 2.28 (s, 3H, H
cy5), 1.11 (d, 3H,
(32) Bennett, M. A.; Smith, A. K. J. Chem. Soc., Dalton Trans. 1974,
233.
(33) Kiel,W.A.;Ball,R.G.;Graham,W.A.G.J.Organomet.Chem.









13C NMR (125 MHz, CD3OD): δ 166.5 (Cq, C
14).
156.6 (Cq, C
16), 155.3 (CH, C
18), 148.0 (Cq, C













2), 121.9 (CH, C
1), 121.7 (CH, C














cy1), 74.4 (CH, C
cy10
), 31.2 (CH, C
cy3), 21.3 (CH3,
C
cy4), 20.9 (CH3, C
cy40
), 17.7 (CH3, C





nium(II) Chloride (3a). General procedure B: N-(2-Fluoro-5,11-
dihydroindolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-2-yl-eth-
ylidene)azine(180mg,0.49mmol),[RuCl2(p-cymene)2]2(149mg,
0.24 mmol), ethanol (4 mL). Yield: 287 mg, 87% (orange solid).
Anal. Calcd for C32H30N5FCl2Ru31.25H2O( Mr 698.11): C,
55.05; H, 4.69; N, 10.03. Found: C, 55.04; H, 4.38; N, 9.94.
ESI-MS (methanol), positive: m/z 640 [M - Cl]
þ. IR (ATR,
selected bands, νmax): 3656, 3350, 3069, 2967, 1638, 1596, 1532,











3J = 8.0 Hz, H
21), 7.93 (dd, 1H, J = 8.9, 2.1 Hz, H
1),
7.78-7.73 (m, 2H, H
4þH
19), 7.71 (d, 1H,
3J = 8.2 Hz, H
10),
7.54-7.50 (m, 1H, H








cy1), 5.65 (d, 1H,
3J = 6.2 Hz, H
cy20
), 5.22 (d, 1H,
3J = 6.2 Hz,
H
cy10
), 2.87-2.79 (m, 1H, H
cy3), 2.78 (s, 3H, H
15), 2.22 (s, 3H,
H
cy5), 1.15 (d, 3H,
3J = 6.9 Hz, H
cy40
), 1.11 (d, 3H,

















4J = 2.5 Hz, C
11a), 133.1 (d, Cq,








7), 121.6 (CH, C
8), 118.7 (d, CH,
3J =8H z ,C
4),
117.1 (d, CH,
2J =2 5H z ,C
3), 114.2 (d, Cq,
3J = 9 Hz, C
11b),
111.6 (CH, C
10), 107.3 (d, CH,
2J =2 5H z ,C
1), 104.8 (Cq, C
6a),
104.6 (Cq, C
cy2a), 103.7 (Cq, C




cy2), 85.7 (CH, C
cy1), 84.1 (CH, C
cy10
), 31.0 (CH, C
cy3),
21.0 (CH3, C
cy4), 20.7 (CH3, C
cy40
), 17.8 (CH3, C
cy5), 14.4 (CH3,
C




(II) Chloride (3b). General procedure B: N-(2-Fluoro-5,11-
dihydroindolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-2-yl-eth-
ylidene)azine(180mg,0.49mmol),[OsCl2(p-cymene)2]2(193mg,
0.24 mmol), ethanol (4 mL). Yield: 333 mg, 90% (orange solid).
Anal.CalcdforC32H30N5FCl2Os31.5H2O(Mr791.77):C,48.54;
H, 4.20; N, 8.85. Found: C, 48.62; H, 3.99; N, 8.66. ESI-MS
(methanol), positive: m/z 730 [M - Cl]
þ,6 9 4[ M- Cl - HCl]
þ.
IR (ATR, selected bands, νmax): 3648, 3350, 3163, 3067, 2966,











7.92 (dd, 1H, J = 8.9, 2.8 Hz, H
1), 7.77-7.73 (m, 1H, H
19), 7.71
(d, 1H,
3J = 8.2 Hz, H
10), 7.61 (dd, 1H, J =8 . 2þ 4.6 Hz, H
4),
7.53-7.49 (m, 1H, H









), 5.88 (d, 1H,
3J = 5.8 Hz, H
cy1), 5.34 (d, 1H,
3J = 5.8 Hz,
H
cy10
), 2.86 (s, 3H, H
15), 2.75-2.66 (m, 1H, H
cy3), 2.28 (s, 3H,
H
cy5), 1.10 (d, 3H,
3J = 7.0 Hz, H
cy40
), 1.07 (d, 3H,

















4J = 2.7 Hz, C
11a), 132.9 (d, Cq,








7), 121.6 (CH, C
8), 118.6 (d, CH,
3J = 9 Hz, C
4),
117.1 (d, CH,
2J =2 5H z ,C
3), 114.1 (d, Cq,
3J = 9 Hz, C
11b),
111.6 (CH, C
10), 107.3 (d, CH,
2J =2 5H z ,C
1), 104.5 (Cq, C
6a),
96.9 (Cq, C
cy1a), 95.7 (Cq, C




cy2), 76.2 (CH, C
cy1), 74.5 (CH, C
cy10
), 31.2 (CH, C
cy3),
21.3 (CH3, C
cy4), 20.9 (CH3, C
cy40
), 17.7 (CH3, C
cy5), 14.2
(CH3, C




ruthenium(II) Chloride (4a). General procedure B: N-(2-Chloro-
5,11-dihydroindolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-2-yl-
methylidene)azine (200 mg, 0.54 mmol), [RuCl2(p-cymene)2]2
(188 mg, 0.27 mmol), ethanol (4.5 mL). Yield: 344 mg, 94%
(orange-yellow solid). Anal. Calcd for C31H28N5Cl3Ru30.5H2O
(Mr687.02):C,54.19;H,4.25;N,10.19.Found:C,54.17;H,4.28;
N, 9.96. ESI-MS (methanol), positive: m/z 642 [M - Cl]
þ.I R
(ATR, selected bands, νmax): 3665, 3382, 3025, 2963, 2867, 2648,










7), 8.17-8.12 (m, 1H, H
20), 8.11 (d, 1H,
4J = 2.3 Hz, H
1), 7.92
(d, 1H,
3J = 7.6 Hz, H
21), 7.75 (d, 1H,
3J =8 . 8H z ,H
4), 7.73-
7.67 (m, 2H, H
10þH
19), 7.54 (dd, 1H,
3J = 8.8 Hz,
4J = 2.3 Hz,
H
3), 7.53-7.49 (m, 1H, H
9), 7.37-7.33 (m, 1H, H
8), 5.87 (d, 1H,
3J = 6.2 Hz, H
cy2), 5.65 (d, 1H,
3J = 6.2 Hz, H
cy1), 5.61 (d, 1H,
3J = 6.2 Hz, H
cy20
), 5.22 (d, 1H,















NMR (125 MHz, CD3OD): δ 157.0 (CH, C
14). 155.5 (CH, C
18),
154.7 (Cq, C





11a), 134.8 (Cq, C
4a), 129.4 (CH, C








7), 121.6 (CH, C
8), 121.4 (CH, C
1), 118.4 (CH, C
4), 114.5 (Cq,
C
11b), 111.6 (CH, C
10), 105.3 (Cq, C
cy2a), 104.7 (Cq, C
6a), 103.7
(Cq, C
cy1a), 86.9 (CH, C
cy20





), 31.1 (CH, C
cy3), 21.0 (CH3, C








(II) Chloride (4b). General procedure B: N-(2-Chloro-5,11-
dihydroindolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-2-yl-meth-
ylidene)azine (200 mg, 0.54 mmol), [OsCl2(p-cymene)2]2 (213 mg,
0.27 mmol), ethanol (4.5 mL). Yield: 347 mg, 84% (orange-red
solid). Anal. Calcd for C31H28N5Cl3Os3H2O( Mr 785.19): C,
47.42; H, 3.85; N, 8.92. Found: C, 47.31; H, 3.81; N, 8.67. ESI-
MS (methanol), positive: m/z 732 [M - Cl]
þ,6 9 6[ M- Cl -
HCl]
þ. IR (ATR, selected bands, νmax): 3654, 2965, 2872, 1630,
1588, 1518, 1454, 1397, 1371, 1333, 1224, 1011, 773, 745, 693, 651
cm
-1.
1H NMR(500MHz,CD3OD):δ9.38 (d, 1H,
3J =5 . 7H z ,
H
18), 9.12 (s, 1H, H
14), 8.36 (d, 1H,














7.53-7.49 (m, 1H, H
9), 7.40-7.36 (m, 1H, H
8), 6.17 (d, 1H,
3J =
5.9 Hz, H
cy2), 5.92-5.88 (m, 2H, H
cy1þH
cy20








3J =6 . 9H z ,H
cy40
), 1.07 (d, 3H,
3J =6 . 9H z ,H




13C NMR (125 MHz, CD3OD): δ 158.2 (CH,
C
14), 156.0 (Cq, C
16), 155.1 (CH, C








3), 128.5 (Cq, C
2), 127.2 (CH, C
19), 126.1 (CH, C
21), 125.1 (CH,
C
9), 123.3 (Cq, C
6b), 122.0 (CH, C
7), 121.6 (CH, C
8), 121.4 (CH,
C
1), 118.3 (CH, C
4), 114.4 (Cq, C









cy2), 76.5 (CH, C
cy1), 74.7 (CH, C
cy10
), 31.3 (CH, C
cy3), 21.2
(CH3, C
cy4), 20.9 (CH3, C
cy40
), 17.6 (CH3, C




(II) Chloride (5a). General procedure B: N-(2-Chloro-5,11-dihy-
droindolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-2-yl-ethylidene)-
hydrazine (200 mg, 0.52 mmol), [RuCl2(p-cymene)2]2 (174 mg,
0.28 mmol), ethanol (4.7 mL). Yield: 262 mg, 73% (yellow solid).
Anal. Calcd for C32H30N5Cl3Ru31.5H2O( Mr 719.07): C, 53.45;
H, 4.63; N, 9.74. Found: C, 53.28; H, 4.51; N, 9.65. ESI-MS278 Organometallics, Vol. 30, No. 2, 2011 Filak et al.
(methanol), positive: m/z 656 [M - Cl]
þ. IR (ATR, selected
bands, νmax): 3656, 3357, 3146, 3063, 2966, 1628, 1589, 1536,






18), 8.50 (d, 1H,
3J = 7.9 Hz, H




20), 8.13 (d, 1H,








4), 7.53-7.49 (m, 2H, H
3þH
9), 7.43-7.39 (m, 1H, H
8),
5.90 (d, 1H,
3J = 6.2 Hz, H
cy2), 5.67 (d, 1H,









2.86-2.76 (m, 1H, H
cy3þs, 3H, H
15), 2.21 (s, 3H, H
cy5), 1.15 (d,
3H,















20), 138.9 (Cq, C
10a), 137.8 (Cq, C








9), 123.5 (Cq, C
6b), 121.9 (CH, C
7), 121.6 (CH, C
8), 121.3
(CH, C
1), 118.4 (CH, C
4), 114.5 (Cq, C
11b), 111.6 (CH, C
10),
104.8 (Cq, C
6a), 104.6 (Cq, C




), 86.0 (CH, C
cy2), 85.7 (CH, C














(II) Chloride (5b). General procedure B: N-(2-Chloro-5,11-
dihydroindolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-2-yl-eth-
ylidene)azine(200mg,0.52mmol),[OsCl2(p-cymene)2]2(205mg,
0.27 mmol), ethanol (4.5 mL). Yield: 320 mg, 79% (orange-
yellowsolid).Anal.CalcdforC32H30N5Cl3Os32H2O(Mr817.23):
C, 47.03; H, 4.19; N, 8.57. Found: C, 46.81; H, 4.06; N, 8.39. ESI-
MS (methanol), positive: m/z 746 [M - Cl]
þ,7 1 0[ M- Cl -
HCl]
þ. IR (ATR, selected bands, νmax): 3656, 3360, 3161, 2965,
1629, 1590,1532, 1457,1395, 1331,1256, 1016,812, 783, 743, 694,
640 cm
-1.
1H NMR (500 MHz, CD3OD): δ 9.43 (d, 1H,
3J =5 . 6
Hz, H
18), 8.46 (d, 1H,
3J = 7.9 Hz, H








10), 7.58 (d, 1H,
3J =8 . 8H z ,H
4), 7.55-7.49 (m, 2H, H
3þH
9),
7.42-7.38 (m, 1H, H
8), 6.19 (d, 1H,
3J = 5.8 Hz, H
cy2), 5.94 (d,
1H,
3J = 5.7 Hz, H
cy20
), 5.88 (d, 1H,
3J = 5.8 Hz, H
cy1), 5.36 (d,
1H,
3J = 5.7 Hz, H
cy10
), 2.86 (s, 3H, H
15), 2.75-2.66 (m, 1H,
H
cy3), 2.28 (s, 3H, H
cy5), 1.11 (d, 3H,









MHz, CD3OD): δ 166.9 (Cq, C
14), 156.4 (Cq, C
16), 155.3 (CH,
C
18), 147.7 (Cq, C
6), 139.6 (CH, C
20), 138.9 (Cq, C
10a), 137.8 (Cq,
C
11a), 134.8 (Cq, C
4a), 129.3 (CH, C








7), 121.6 (CH, C
8), 121.3 (CH, C
1), 118.3 (CH, C
4), 114.4 (Cq,
C
11b), 111.6 (CH, C
10), 104.5 (Cq, C
6a), 96.9 (Cq, C
cy1a), 95.8 (Cq,
C
cy2a), 79.2 (CH, C
cy20
), 77.7 (CH, C




), 31.2 (CH, C
cy3), 21.3 (CH3, C









(II) Chloride (6a). General procedure B: N-(2-Bromo-5,11-
dihydroindolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-2-yl-eth-
ylidene)azine (200 mg, 0.47 mmol), [RuCl2(p-cymene)2]2(142 mg,
0.23 mmol), ethanol (4.2 mL). Yield: 234 mg, 68% (yellow solid).
Anal. Calcd for C32H30N5Cl2BrRu31.5H2O( Mr 763.52): C,
50.34; H, 4.36; N, 9.17. Found: C, 50.16; H, 4.18; N, 9.08. ESI-
MS (methanol), positive: m/z 702 [M - Cl]
þ. IR (ATR, selected
bands,νmax):3652,3359,3217,3142,2966,1626,1586,1534,1455,
1393, 1331, 1222, 1014, 812, 744, 712, 693, 642, 577 cm
-1.
1H
NMR(500MHz,CD3OD): δ9.50 (d, 1H,













3J = 7.9, 5.6 Hz,
4J =1 . 3H z ,H
19), 7.71 (d, 1H,
3J =8 . 2H z ,H
10), 7.66-7.62 (m, 2H, H
3þH






3J =6 . 2H z ,H
cy2), 5.67 (d, 1H,
3J =6 . 2H z ,H
cy1), 5.65 (d,
1H,
3J = 6.1 Hz, H
cy20
), 5.22 (d, 1H,
3J = 6.1 Hz, H
cy10
),
2.86-2.76 (s, 3H, H
15 þ m, 1H, H
cy3), 2.22 (s, 3H, H
cy5), 1.15
(d, 3H,
3J = 7.0 Hz, H
cy40
), 1.11 (d, 3H,
3J =6 . 9H z ,H






14), 155.5 (CH, C
18), 155.4 (Cq, C













1), 123.5 (Cq, C
6b), 121.9 (CH, C
7), 121.6 (CH, C
8), 118.6 (CH,
C
4), 115.4 (Cq, C
2), 114.9 (Cq, C
11b), 111.6 (CH, C
10), 104.8 (Cq,
C
6a), 104.6 (Cq, C
cy2a), 103.7 (Cq, C




cy2), 85.7 (CH, C
cy1), 84.2 (CH, C
cy10
), 31.1 (CH, C
cy3),
21.0 (CH3, C
cy4), 20.7 (CH3, C
cy40
), 17.8 (CH3, C
cy5), 14.5 (CH3,
C




(II) Chloride (6b). General procedure C: N-(2-Bromo-5,11-dihy-
droindolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-2-yl-ethylidene)-
azine (200 mg, 0.47 mmol), [OsCl2(p-cymene)2]2 (184 mg, 0.23
mmol), ethanol (4 mL). Yield: 231 þ 106 mg, 88% (red solid).
Elemental analysis of pure product was obtained by dissolution of
the first crop in methanol and filtration through a GF3-filter,
followed by evaporationofthe solventunderreduced pressureand
drying in vacuo at 45 C. Anal. Calcd for C32H30N5BrCl2Os (Mr
825.65): C, 46.55; H, 3.66; N, 8.48. Found: C, 46.40; H, 3.62; N,
8.41. ESI-MS (methanol), positive: m/z 790 [M - Cl]
þ,7 5 4[ M-
Cl - HCl]
þ. IR (ATR, selected bands, νmax): 3615, 3232, 2965,
2748,1625,1585,1454,1402,1332,1222,1155,1023,811,784,749,
695, 641, 617, 576 cm
-1.
1H NMR (500 MHz, CD3OD): δ9.43 (d,
1H,
3J =5 . 5H z ,H
18), 8.45 (d, 1H,
3J =7 . 9H z ,H






19), 7.70 (d, 1H,
3J =8 . 0H z ,H
10), 7.64 (dd, 1H,
3J =8 . 7H z ,
4J=1 . 9H z ,H
3), 7.53-7.47 (m,2H, H
4þH
9), 7.42-7.37 (m, 1H,
H
8), 6.18 (d, 1H,
3J =5 . 6H z ,H
cy2), 5.92 (d, 1H,
3J =5 . 7H z ,
H
cy20
), 5.87 (d, 1H,
3J = 5.6 Hz, H
cy1), 5.34 (d, 1H,
3J = 5.7 Hz,
H
cy10
), 2.86 (s, 3H, H
15), 2.74-2.65 (m, 1H, H
cy3), 2.27 (s, 3H,
H
cy5), 1.10 (d, 3H,
3J = 6.8 Hz, H
cy40
), 1.06 (d, 3H,
3J = 6.9 Hz,
H




















1), 123.5 (Cq, C
6b), 121.8 (CH, C
7), 121.6 (CH, C
8),
118.5 (CH, C
4), 115.4 (Cq, C
2), 114.9 (Cq, C















cy4), 20.8 (CH3, C
cy40
), 17.7 (CH3, C
cy5), 14.3 (CH3,
C






azine (180 mg, 0.49 mmol), [RuCl2(p-cymene)2]2 (151 mg, 0.25
mmol), ethanol (4 mL). Yield: 173 þ 133 mg, 92% (bright orange
solid).Anal.CalcdforC33H33N5Cl2Ru3H2O(Mr689.64):C,57.47;
H, 5.12; N, 10.16. Found: C, 57.45; H, 4.89; N, 10.16. ESI-MS
(methanol), positive: m/z636[M - Cl]
þ. IR (ATR, selected bands,
νmax): 3655, 3336, 3155, 3064, 2964, 1638, 1586, 1528, 1460, 1427,
1392, 1335, 1223, 812, 780, 744, 706, 643 cm
-1.
1HN M R( 5 0 0
MHz, CD3OD): δ 10.54 (br s, 1H, H
5), 9.49 (d, 1H,
3J =5 . 5H z ,
H
18), 8.49 (d, 1H,
3J =7 . 9H z ,H








3J =8 . 2H z ,H
10), 7.63 (d, 1H,
3J =8 . 4H z ,H
4),
7.50-7.46 (m, 1H, H
9), 7.41-7.37 (m, 2H, H
3þH
8), 5.87 (d, 1H,
3J =6 . 0H z ,H
cy2), 5.63 (d, 1H,
3J =6 . 0H z ,H
cy1), 5.60 (d, 1H,
3J =6 . 0H z ,H
cy20
), 5.13 (d, 1H,










3J =6 . 9H z ,H
cy40
), 1.10 (d, 3H,
3J =6 . 9H z ,H
cy4)p p m ,H
11
not obsd.
13C NMR (125 MHz, CD3OD): δ 165.1 (Cq, C
14). 155.7
(Cq, C
16), 155.4 (CH, C
18), 147.8 (Cq, C
6), 139.4 (CH, C
20),
139.2 (Cq, C
11a), 138.8 (Cq, C
10a), 134.4 (Cq, C
4a), 133.1 (Cq, C
2),
130.7 (CH, C
3), 126.3 (CH, C
19), 125.5 (CH, C
21), 124.6 (CH, C
9),
123.7 (Cq, C
6b), 121.8 (CH, C
7), 121.5 (CH, C
1), 121.3 (CH, C







6a), 103.8 (Cq, C










cy4), 20.7 (CH3, C
cy40
), 19.8 (CH3, C
20







(II) Chloride (7b). General procedure C: N-(2-Methyl-5,11-
dihydroindolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-2-yl-eth-
ylidene)azine (180 mg, 0.49 mmol), [OsCl2(p-cymene)2]2 (195 mg,
0.25 mmol), ethanol (4 mL). Yield: 244 þ 82 mg, 87% (red
solid). Elemental analysis of pure product was obtained by
dissolutionofthefirstcropinmethanolandfiltrationthrougha
GF3-filter, followed by evaporation of the solvent under
reduced pressure and drying in vacuo at 47 C. Anal. Calcd
forC33H33N5Cl2Os30.75H2O(Mr774.30):C,51.19;H,4.49;N,
9.04. Found: C, 51.23; H, 4.51; N, 8.93. ESI-MS (methanol),
positive: m/z 726 [M - Cl]
þ,6 9 0[ M- Cl - HCl]
þ.I R( A T R ,
selected bands, νmax): 3656, 3336, 3173, 3059, 2965, 2869, 1636,





5), 9.42 (d, 1H,
3J = 5.6 Hz, H
18), 8.45 (d, 1H,
3J = 7.8 Hz,
H
7), 8.24-8.19 (m, 2H, H
20þH



















cy1), 5.26 (d, 1H,
3J = 5.8 Hz, H
cy10
), 2.86 (s, 3H, H
15),
2.72-2.65 (m, 1H, H
cy3), 2.52 (s, 3H, H
20
), 2.27 (s, 3H, H
cy5),
1.10 (d, 3H,
3J = 7.0 Hz, H
cy40
), 1.06 (d, 3H,






14). 156.6 (Cq, C
16), 155.3 (CH, C
18), 148.0 (Cq, C
6),
139.5 (CH, C
20), 139.1 (Cq, C
11a), 138.8 (Cq, C
10a), 134.2 (Cq,
C
4a), 133.1 (Cq, C
2), 130.7 (CH, C
3), 127.2 (CH, C
19), 125.7
(CH, C
21), 124.6 (CH, C
9), 123.7 (Cq, C
6b), 121.7 (CH, C
7),
121.5 (CH, C
1), 121.3 (CH, C
8), 116.7 (CH, C
4), 113.0
(Cq, C
11b), 111.4 (CH, C
10), 103.9 (Cq, C
6a), 97.1 (Cq, C
cy1a),
95.5 (Cq, C
cy2a), 79.3 (CH, C
cy20
), 77.7 (CH, C
cy2), 75.9 (CH,
C
cy1), 74.3 (CH, C
cy10
), 31.2 (CH, C




), 19.8 (CH3, C
20











Anal. Calcd for C32H30N6O2Cl2Ru30.5H2O( Mr 711.60): C,
54.01; H, 4.39; N, 11.81. Found: C, 53.75; H, 4.17; N, 11.61.
ESI-MS (methanol), positive: m/z 667 [M - Cl]
þ. IR (ATR,
selected bands, νmax): 3330, 3036, 2964, 1627, 1594, 1520, 1459,
1402,1331,1282,1221,1156,1091,1019,826,771,743,695cm
-1.
1H NMR (500 MHz, CD3OD): δ 9.53 (d, 1H,
3J =5 . 7H z ,H
18),
9.17 (d, 1H,
4J =2. 3H z,H
1), 8.51 (d, 1H,
3J = 7.8Hz, H
7), 8.38
(dd, 1H,
3J =9 . 1H z ,
4J = 2.5 Hz, H
3), 8.29-8.25 (m, 1H, H
20)
8.18 (d, 1H,
3J = 8.1 Hz, H
21), 7.82 (d, 1H,







9) 7.46-7.42 (m, 1H, H
8), 5.95 (d, 1H,
3J = 6.3 Hz,
H
cy2), 5.74-5.70 (m, 2H, H
cy1þH
cy20
), 5.33 (d, 1H,
3J = 6.1 Hz,
H
cy10
), 2.89-2.81 (m, 1H, H
cy3), 2.79 (s, 3H, H
15), 2.24 (s, 3H,
H
cy5), 1.17 (d, 3H,
3J = 6.9 Hz, H
cy40
), 1.13 (d, 3H,












2), 140.2 (Cq, C




11a), 127.8 (CH, C
19), 126.3 (CH, C
21), 125.4 (CH,
C
9), 123.9 (CH, C
3), 123.4 (Cq, C








6a), 96.9 (Cq, C
cy1a), 96.2 (Cq, C




cy2), 76.4 (CH, C
cy1), 74.7 (CH, C
cy10
), 31.3 (CH, C
cy3),
21.3 (CH3, C
cy4), 20.9 (CH3, C
cy40
), 17.7 (CH3, C
cy5), 14.3 (CH3,
C




(II) Chloride (8b). General procedure C: N-(2-Nitro-5,11-dihy-
droindolo[3,2-c]quinolin-6-ylidene)-N0-(1-pyridin-2-yl-ethylidene)-
azine (152 mg, 0.38 mmol), [OsCl2(p-cymene)2]2 (152 mg, 0.19
mmol), ethanol (3.8 mL). Yield: 234 mg, 77% (brown solid).
Elemental analysis of pure product was obtained by dissolution
ofthefirstcropinmethanol(60mL) andfiltrationthroughaGF3-
filter, followed by evaporation of the solvent under reduced
pressure and drying in vacuo at 47 C. Anal. Calcd for C32H30-
N6O2Cl2Os3H2O(Mr809.77): C, 47.46; H, 3.98; N, 10.38. Found:
C, 47.41; H, 3.81; N, 10.14. ESI-MS (methanol), positive: m/z 757
[M-Cl]
þ,7 21[M-Cl -HCl]
þ. IR (ATR, selectedbands, νmax):
3337, 3038, 2964, 1627, 1600, 1521, 1459, 1404, 1331, 1282, 1220,
1156, 1140, 1018, 827, 772, 742, 700 cm
-1.
1H NMR (500 MHz,
CD3OD): δ 9.46 (d, 1H,
3J =5 . 6H z ,H
18), 9.17 (d, 1H,







=2 . 5H z ,H
3), 8.30-8.23 (m, 2H, H
20þH







7.56-7.52 (m, 1H, H
9), 7.45-7.41 (m, 1H, H









cy1), 5.47 (d, 1H,
3J =5 . 7H z ,H
cy10
), 2.87 (s, 3H, H
15),
2.78-2.69 (m, 1H, H
cy3), 2.30 (s, 3H, H
cy5), 1.13 (d, 3H,
3J =7 . 0
Hz, H
cy40
), 1.09 (d, 3H,








16), 155.4 (CH, C
18), 147.3 (Cq, C








19), 126.3 (CH, C
21), 125.4 (CH, C
9), 123.9 (CH, C
3), 123.4 (Cq,
C
6b), 121.9 (CH, C
8), 121.8 (CH, C
7), 118.2 (CH, C
1), 113.3 (Cq,
C
11b), 111.8 (CH, C
10), 104.8 (Cq, C










), 31.3 (CH, C
cy3), 21.3 (CH3, C




cy5), 14.3 (CH3, C
15) ppm.
Crystallographic Structure Determination. X-ray diffraction
measurements were performed on a Bruker X8 APEXII CCD
diffractometer. Single crystals were positioned at 40, 40, 40, 40,
40, and 35 mm from the detector, and 1304, 1131, 1919, 1565,
1936,and1059framesweremeasured,eachfor40,60,20,30,30,
and 90 s over 1,1 ,1 ,1 ,1 , and 0.5 scan width for 2a, 4a, 4b,
5a, 7a, and 7b, correspondingly. The data were processed using
SAINT software.
34 Crystal data, data collection parameters,
and structure refinement details are given in Table 2. The struc-
tures were solved by direct methods and refined by full-matrix
least-squares techniques. Non-H atoms for 2a, 4a, 4b, 5a, 7a,
and 7b were refined with anisotropic displacement parameters
(except those of cocrystallized disordered solvent molecules). H
atoms were inserted in calculated positions and refined with a
ridingmodel.Refinementofthestructureof2arevealedthatthe
arene occupies two statistically disordered positions (rotational
disorder around the Ru-arenecentroid). The disorder was re-
solved with constrained isotropic displacement parameters and
restrained bond distances using EADP and SADI instruc-
tions of SHELX97, respectively. The site occupation factors
(sof)were refined to about 0.60:0.40. The Cl2 counterion was
also found disordered over two positions with sof 0.55:
0.45. The following software programs and computer were
used: structure solution and refinement, SHELXS-97 and
SHELXL-97;
35 molecular diagrams, ORTEP-3;
36 computer,
Intel CoreDuo.
Cell Lines and Culture Conditions. CH1 (ovarian carcinoma,
human) cells were donated by Lloyd R. Kelland (CRC Centre
for Cancer Therapeutics, Institute of Cancer Research, Sutton,
U.K.). SW480 (colon adenocarcinoma, human) cells and A549
(non-small-cell lung cancer, human) cells were kindly provided
(34) SAINT-Plus, version 7.06a, and APEX2; Bruker-Nonius AXS
Inc.: Madison, WI, 2004.
(35) Sheldrick, G. M. Acta Crystallogr. 2008, A64, 112.
(36) Johnson, G. K. Report ORNL-5138; OAK Ridge National
Laboratory: Oak Ridge, TN, 1976.280 Organometallics, Vol. 30, No. 2, 2011 Filak et al.
by Brigitte Marian (Institute of Cancer Research, Department
of Medicine I, Medical University of Vienna, Austria). All cell
culturemediaandreagentswerepurchasedfromSigma-Aldrich
Austria. Cells were grown without antibiotics in 75 cm
2 culture
flasks (Iwaki/Asahi Technoglass) as adherent monolayer cul-
tures in Minimal Essential Medium (MEM) supplemented with
10%heat-inactivatedfetalbovineserum,1mMsodiumpyruvate,
and 2 mM L-glutamine. Cultures were maintained at 37 Ci na
humidified atmosphere containing 5% CO2 and 95% air.
Cytotoxicity in Cancer Cell Lines. Cytotoxicity in the cell
lines mentioned above was determined by the colorimetric
MTTassay(MTT=3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide). For this purpose, cells were harvested
from culture flasks by trypsinization and seeded in aliquots of
100 μL/well into 96-well microculture plates (Iwaki/Asahi
Technoglass) in the following densities, in order to ensure
exponential growth of untreated controls throughout the ex-
periment: 1.5   10
3 (CH1), 2.5   10
3 (SW480), and 4.0   10
3
(A549) viable cells per well. Cells were allowed to settle and
resume exponential growth in drug-free MEM supplemented
with 10% heat-inactivated fetal bovine serum, 1 mM sodium
pyruvate, 4 mM L-glutamine, and 1% nonessential amino acids
(100 stock)for24h.DMSOstocksofthetestcompoundswere
serially diluted in the same medium and added to the plates in
aliquots of 100 μL/well such that the maximum DMSO content
did not exceed 0.5%. After continuous exposure for 96 h,
medium was replaced by 100 μL/well RPMI 1640 medium
(supplemented with 10% heat-inactivated fetal bovine serum
and 4 mM L-glutamine) plus 20 μL/well MTT in phosphate-
buffered saline (5 mg/mL). After incubation for 4 h, medium/
MTT mixtures were removed, and the formazan product
formed by viable cells was dissolved in DMSO (150 μL/well).
Optical densities at 550 nm were measured with a microplate
reader (Tecan Spectra Classic), using a reference wavelength of
690 nm to correct for unspecific absorption. The quantity of
viable cells was expressed as percentage of untreated controls,
and 50% inhibitory concentrations (IC50) were calculated from
concentration-effectcurvesbyinterpolation.Evaluationisbased
on at least three independent experiments, each comprising three
replicates per concentration level.
Results and Discussion
Synthesis and Characterization of the Ligands and Com-




were prepared in four and three steps, correspondingly, as
shown in Scheme 1. First, by reaction of 2-aminobenzyl-
amine with indole-2,3-diones in acetic acid the indoloquino-
lines A were prepared, which were further chlorinated with
phosphorus oxychloride to derivatives B (Scheme 1).
24,25,29
In the third step species B were allowed to react with excess
hydrazine hydrate to yield indoloquinoline-hydrazines C.
Finally the ligands L
1-L
7 were prepared by condensation
reaction of compounds C with 2-formyl- or 2-acetylpyridine
(Experimental Section, General Procedure A). This reaction
pathway proved to be unsuited for L
8, since upon reaction
withhydrazine, both thenitro group and the imidoylchloride
were reduced. Therefore L
8 was prepared by direct coupling
of 2-acetylpyridine hydrazone with the imidoyl chloride spe-
cies B. Complexation was realized following a conventional
Table 1. Selected Bond Distances (A ˚ ) and Angles (deg) for Complexes 2a, 4a, 4b, 5a, 7a, and 7b
2a 4a 4b 5a 7a 7b
M-Cl 2.4121(9) 2.405(2) 2.4085(18) 2.4149(11) 2.4137(16) 2.421(5)
M-N4 2.100(3) 2.111(6) 2.108(6) 2.078(4) 2.075(5) 2.092(14)
M-N5 2.073(3) 2.101(7) 2.082(5) 2.086(4) 2.075(5) 2.067(14)
M-Carene av 2.188(5)
a 2.204(16) 2.202(12) 2.201(9) 2.202(10) 2.21(1)
Carene-Carene av 1.390 1.419(8) 1.425(5) 1.415(5) 1.409(6) 1.43(1)
N4-M-N5 76.73(12) 76.9(3) 76.4(2) 76.51(14) 76.55(19) 75.8(5)
N4-M-Cl 88.18(9) 88.0(2) 86.10(17) 87.06(11) 87.41(15) 85.5(4)
N5-M-Cl 82.82(9) 84.61(19) 81.53(17) 83.20(11) 83.70(14) 81.9(4)
aThe mean value was calculated only for the first disordered component.
Table 2. Crystal Data and Details of Data Collection for 2a, 4a, 4b, 5a, 7a, and 7b
2a31.7H2O 4a 4b30.25Et2O31.5H2O 5a3EtOH 7a30.5EtOH30.2H2O 7b3H2O
empirical formula C32H34.4Cl2N5O1.7Ru C31H28Cl3N5Ru C32H33.5Cl3N5O1.75Os Ru C34H36Cl3N5ORu C34H36.4Cl2N5O0.7Ru C33H35Cl2N5OOs
fw 688.22 678.00 812.69 738.10 699.26 778.76
space group P21/nI 4 C2/cP 21/nP 21/nC 2/c
a [A ˚ ] 10.4899(3) 26.5354(10) 17.2834(5) 10.7350(4) 10.6834(11) 11.690(2)
b [A ˚ ] 11.8881(3) 26.5354(10) 14.0348(5) 12.0515(4) 12.0598(12) 21.276(4)
c [A ˚ ] 25.1390(8) 9.0872(4) 29.4680(11) 25.1678(9) 25.482(3) 25.898(4)
R [deg]
β [deg] 95.195(2) 106.416(4) 94.293(2) 93.080(7) 102.712(9)
γ [deg]
V [A ˚ 3] 3122.08(16) 6398.5(4) 6856.6(4) 3246.9(2) 3278.3(6) 6283.4(19)
Z 48 8 4 48
λ [A ˚ ] 0.71073 0.71073 0.71073 0.71073 0.71073 0.71073
Fcalcd [g cm
-3] 1.464 1.408 1.575 1.510 1.417 1.646
cryst size [mm
3] 0.25   0.25   0.15 0.30   0.05   0.05 0.50   0.25   0.03 0.30   0.15   0.10 0.15   0.15   0.03 0.35   0.20   0.10
T [K] 100 100 100 100 100 100
μ [mm
-1] 0.710 0.768 3.988 0.766 0.675 4.264
R1
a 0.0504 0.0593 0.0546 0.0542 0.0637 0.0915
wR2
b 0.1363 0.1646 0.1388 0.1581 0.1836 0.2343
GOF



























and p is the total number of parameters refined.Article Organometallics, Vol. 30, No. 2, 2011 281
μ-chlorido bridge splitting reaction of the dimeric starting
materials [(η
6-p-cymene)M
II(μ-Cl)Cl]2,w h e r eM = R u ,O s ,
withmodifiedindoloquinolinesL
1-L
8in dry ethanol, afford-
ing compounds 1a,b-8a,b in 68-94% yield. With the excep-
tion of 6b, all complexes were hydrated. Thermogravimetric
analysis showed that hydrated samples lose water upon heat-
ingwitharateof10C/minto120Cundernitrogenandtake
up water again on cooling and contact with air within 1 h (see




the molecular peak ions [M þ H]
þ. Additional peaks were











II(L)Cl]Cl) was observed. Further, osmium




base peak in all spectra measured indicates the higher
stability of this family of complexes compared to the quite
recently reported metal-arene-based indoloquinolines.
11
Further evidence was provided by UV-vis measurements
of 1a,b-8a,b in 1% DMSO/H2O over 24 h (see Figures S4
and S5 for details). The observed changes in the optical
spectra of the ruthenium complexes were significant, but
smaller than those of the complexes reported previously.
DMSO(1%)didnotinfluencethespectra,ascouldbeshown
by a comparative 24 h run of complex 1a in pure water (data
shown in Figure S4). Attempts to suppress the hydrolysis of
the Ru-Cl bond by addition of sodium chloride resulted in
slowprecipitationofthecomplexes.Noprecipitationoccurred
in the presence of media for the MTT assay (MEM supple-
mented with 10% heat-inactivated fetal bovine serum, 1 mM
sodium pyruvate, 4 mM L-glutamine, and 1% nonessential
amino acids (100 )). The osmium compounds remained
p r a c t i c a l l yi n t a c ti ns o l u t i o no v e r2 4h ,a sd e p i c t e di nF i g u r eS 5 .
The higher stability of osmium than ruthenium compounds is,




13C NMR spectra of the ligands and ruthe-
nium(II)- and osmium(II)-arene complexes indicate their
C1molecularsymmetryinsolution.WhereastheNMRshifts
of the indoloquinoline backbone remained almost unaf-
fected by complexation, the resonances of protons and
carbon atoms forming the five-membered chelate ring were






8.6 ppm in the ligand to 9.4-9.5 ppm in the complex. As
expected for protons neighboring a stereogenic metal center,
four distinct signals were observed for the aromatic protons
of the p-cymene ligands.


















7)Cl]Cl3H2O( 7b3H2O) are shown in
Figures S1, 1-4, and S2, respectively. All complexes have a




ring forming the seat and three other donor atoms (two nitro-
gens, N4 and N5, of indolo[3,2-c]quinoline and one chlorido
ligand) as the legs of the stool. Selected bond distances and
anglesarequotedinTable1.Allcomplexeswiththeexceptionof
4a crystallize as racemates owing to the presence of the stereo-
genic metal center.
Uponbindingtoruthenium(II)orosmium(II),theligands
form a five-membered chelate ring, N4C13C14N5M (M=
Ru, Os). The torsion angle ΘN4-C13-C14-N5, which serves as
ameasureofthedistortionofthechelateringfromplanarity,
is -7.6(5), 0.8(11), -6.5(10), -4.4(6), -4.0, and -6(2)
for 2a, 4a, 4b, 5a, 7a, and 7b, respectively.
Cytotoxicity in Cancer Cell Lines. Cytotoxicity of the
rutheniumcomplexes1a-7aandanalogousosmiumcomplexes
Figure 1. ORTEP view of the cation in 4a with thermal ellip-
soids drawn at the 50% probability level with anintramolecular
hydrogen bonding N2-H333Cl2 [N2-H 0.88, H333Cl2 2.304,
N2333Cl2 3.180 A ˚ ,N 2 -H333Cl2 174.1].
Figure 2. ORTEP view of the cation in 4b30.25(C2H5)2O3
1.5H2O with thermal ellipsoids drawn at the 50% probability
level with an intramolecular hydrogen bonding N2-H333Cl2
[N2-H 0.88, H333Cl2 2.313, N2333Cl2 3.177 A ˚ ,N 2 -H333Cl2
167.3].
(37) Reedijk, J. Platinum Met. Rev. 2008, 52,2 .
(38) Hanif, M.; Henke, H.; Meier, S. M.; Martic, S.; Labib, M.;
Kandioller, W.; Jakupec, M. A.; Arion, V. B.; Kraatz, H.-B.; Keppler,
B. K.; Hartinger, C. G. Inorg. Chem. 2010, 49, 7953.
(39) van Rijt, S. H.; Hebden, A. J.; Amaresekera, T.; Deeth, R. J.;
Clarkson, G. J.; Parsons, S.; McGowan, P. C.; Sadler, P. J. J. Med.
Chem. 2009, 52, 7753.
(40) Hanif, M.; Nazarov, A. A.; Hartinger, C. G.; Kandioller, W.;
Jakupec,M.A.;Arion,V.B.;Dyson,P.J.;Keppler,B.K.DaltonTrans.
2009, 39, 7345.
(41) El-khateeb, M.; Damer, K.; G€ orls, H.; Weigand, W. J. Organo-
met. Chem. 2007, 692, 2227.
(42) Kandioller, W.; Hartinger, C. G.; Nazarov, A. A.; Kuznetsov,
M. L.; John, R. O.; Bartel, C.; Jakupec, M. A.; Arion, V. B.; Keppler,
B. K. Organometallics 2009, 28, 4249.
(43) Zagermann, J.; Kuchta, M. C.; Merz, K.; Metzler-Nolte, N.
J. Organomet. Chem. 2009, 694, 862.
(44) Albrecht, C.; Gauthier, S.; Wolf, J.; Scopelliti, R.; Severin, K.
Eur. J. Inorg. Chem. 2009, 1003.282 Organometallics, Vol. 30, No. 2, 2011 Filak et al.
1b-7b was assessed by means of a colorimetric microculture
assay (MTT assay) in three human cancer cell lines, yielding the
IC50 values listed in Table 3. The uncomplexed indoloquinoline
derivatives L
1-L
8 as well as complexes 8a and 8b could not
be tested because of insufficient solubility. Hence, binding to a
ruthenium-arene or osmium-arene moiety makes this class of
potentially pharmacologically active indoloquinoline deriva-
tives applicable for biological testing in solution, whatever role
the metal may play in the mechanism of action, in particular in
interactions with biological targets.
All compounds tested are potent inhibitors of cancer cell
proliferation in vitro, with IC50 values in the submicromolar
to low micromolar range: 0.19-3.8 μM in the rather chemo-
sensitive ovarian cancer cell line CH1, 0.26-5.0 μM in the
colon carcinoma cell line SW480, and 0.83-14 μM in the
rather chemoresistant non-small-cell lung cancer cell line
A549. 1b is consistently the most active of these compounds,
with IC50 values comparable to those of three related in-
doloquinoline complexes reported previously.
11 A compar-
ison with simple cymene complexes of ruthenium(II) with
coordination to one chlorido ligand and two N-donors,
such as NH3 or ethylenediamine (en), shows that the pre-
sence of an indoloquinoline ligand is mostly advantageous.
All of the ruthenium complexes 1a-7a are much more
cytotoxic than [(η
6-p-cymene)Ru
II(NH3)2Cl](PF6)( I C 50
values >200 μM), and in the majority of cases they are
at least as cytotoxic (up to 10 times more potent in a few
cases) as [(η
6-p-cymene)Ru
II(en)Cl](PF6) (IC50 values: 4.4,
3.5, and 7.1 μM in CH1, SW480, and A549 cells,
respectively).
5
Generally, the impact of most structural modifications
on cytotoxicity is not dramatic, and structure-activity rela-
tionships are blurred by overlapping ranges of variation.
Mostly, the complexes of the formylpyridine series
tend to be at least as cytotoxic as their analogues of the
acetylpyridine series, and most osmium complexes show
cytotoxic potencies either somewhat higher than or at least
similar to those of the corresponding ruthenium complexes.
Variation of the substituent R
1 in the complexes of the
acetylpyridine series yields the following pattern, which is
illustrated by the concentration-effect curves depicted in
Figure S6: The presence of a halogen atom in complexes 3a,
3b, 5a, 5b, 6a, and 6b in position 2 results in an up to 5.4-fold
lowered impact on cell viability compared to complexes 2a
and 2b,lacking a substituentin this position. In contrast, the
presence of a methyl substituent results in either comparable
cytotoxicity (osmium complex 7b) or 2- to 4-fold enhanced
cytotoxicity (ruthenium complex 7a) compared to the corre-
sponding unsubstituted analogues and 3-15 times higher
cytotoxicity compared to the corresponding fluoro analo-
gues 3a and 3b, containing the most electronegative substi-
tuent. Even though variation of the halogen group (F, Cl, or
Br) does not yield a uniform pattern, these observations
suggest that electron-withdrawing substituents tend to be
disadvantageous for cytotoxic potency, whereas an electron-
donating methyl substituent is not.
Final Remarks. The reported results establish synthetic
access to a new family of ruthenium(II)- and osmium(II)-
arene complexes with 2-substituted indoloquinolines. The
metal-free modified indoloquinolines could not be tested for
antiproliferative activity because of their insufficient solubi-
lity in biological media. Binding to ruthenium(II)- and
osmium(II)-arene moieties resulted in complexes with
improved solubility, enabling most of them to be tested as
potential antitumor agents. The use of iminopyridines as
chelating moieties instead of ethylenediamine ones afforded
complexesthataremarkedlymorestableinaqueoussolution
containing 1% DMSO. As expected, the osmium(II)
Figure 3. ORTEP view of the cation in 5a3C2H5OH with
thermal ellipsoids drawn at the 50% probability level with an
intramolecular hydrogen bonding N2-H333Cl2 [N2-H 0.88,
H333Cl2 2.340, N2333Cl2 3.176 A ˚ ,N 2 -H333Cl2 158.8].
Figure 4. ORTEP view of the cation in 7a30.5C2H5OH3
0.2H2O with thermal ellipsoids drawn at the 40% probability
level with an intramolecular hydrogen bonding N2-H333Cl2
[N2-H 0.88, H333Cl2 2.363, N2333Cl2 3.207 A ˚ ,N 2 -H333Cl2
160.9].
Table 3. Cytotoxicity of Ruthenium and Osmium Arene-Based
Indoloquinoline Complexes in Three Human Cancer Cell Lines
IC50 (μM)
a
compound CH1 SW480 A549
1a 2.2(0.6 2.1(0.4 6.0(1.5
1b 0.19(0.06 0.26(0.03 0.83(0.19
2a 0.70(0.06 1.0(0.2 4.6(0.8
2b 0.24(0.02 1.0 (0.2 1.8(0.3
3a 2.8(0.9 2.3(1.0 14(3
3b 1.2(0.5 2.9(0.6 10 (3
4a 0.32 (0.13 0.76(0.03 5.1( 1.8
4b 0.42 (0.05 0.51(0.04 1.8( 0.2
5a 3.8( 0.6 5.0(1.0 9.3(3.4
5b 0.55(0.14 1.2(0.3 3.9(0.5
6a 1.3(0.2 1.5(0.6 7.2(1.7
6b 1.0(0.4 2.3( 0.4 7.8(2.1
7a 0.19(0.02 0.28(0.02 2.0(0.4
7b 0.19(0.08 0.57(0.20 3.2(0.4
a50% inhibitory concentrations (means ( standard derivations), as
obtained by the MTT assay (continuous exposure for 96 h).Article Organometallics, Vol. 30, No. 2, 2011 283
complexes were more stable than the ruthenium(II) conge-
ners and practically remained intact over 24 h according to
optical spectra measurements. All complexes show remark-
ably high antiproliferative activities in human cancer cell lines
with IC50 values in the 10
-7 to 10
-5 M concentration range,
depending on the cell line. Like in the case of paullones, the
electronicpropertiesofsubstituentsinposition2havenodis-
tinct effect on cytotoxicity,
45,46 although electron-withdrawing
substituentstendtobedisadvantageousforcytotoxicactivity,
whereas anelectron-donatingmethyl groupis not. Theformyl-
pyridine series was at least as active as the acetylpyridine
analogues. Clear-cut structure-activity relationships were
often hindered by overlapping ranges of variation.
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